Skip to main content
Premium Trial:

Request an Annual Quote

Intrinsic Bioprobes Receives US Patent for Protein Biomarkers for Myocardial Infarction

Premium

Biomarker discovery firm Intrinsic Bioprobes announced this week that it has been granted a US patent for biomarkers and assays for the determination of myocardial infarction.

According to the patent, US No. 7,816,095, the company identified the proteins serum amyloid A and S-sulfonated transthyretin as biomarkers for myocardial infarction and developed a three-marker panel consisting of SAA, SS-TTR, and known MI biomarker myoglobin that in a 192-sample study demonstrated predictive power exceeding that of conventional MI assays.

In addition to being useful for detecting myocardial infarction, the biomarkers are also interesting in that "they clearly demonstrate the significance of protein microheterogeneity in human disease, which has been a largely unexplored niche in human molecular biology," Urban Kiernan, the company's director of biomarker discover, said in a statement.

The biomarkers were discovered using Intrinsic Bioprobe's mass spectrometric immunoassay technology – a patented pipette immunoenrichment method that uses a high-throughput, high-binding-capacity microcolumn activated with antibodies to isolate low-abundance proteins in complex samples. Researchers analyze the isolated proteins via single reaction-monitoring mass spec, which enables them to quantitate protein variants.

In July, the company announced an agreement with Thermo Fisher Scientific to co-develop and market protein biomarker assays based on the technology (PM 07/15/2010).

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.